3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Advanced Malignancies
2
Urothelial Cancer
1
Thyroid Neoplasms
1
Solid Tumors, KRAS Mutation
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Opioid-Related Disorders
1
Lung Neoplasms
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Leiomyosarcoma
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
Hematologic Neoplasms
1
Healthy Adult Participants
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Cancer Pain
1
Interventions
Carboplatin
9
pembrolizumab
7
Pemetrexed
7
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Radiation
4
Nivolumab
4
Bevacizumab
4
Platinum
3
Paclitaxel
3
Mastectomy, Segmental
3
Cisplatin
3
Biopsy
3
fludarabine phosphate
2
durvalumab
2
capmatinib
2
aldesleukin
2
Taxes
2
Radiotherapy, Conformal
2
Radiosurgery
2
Ipilimumab
2
Interleukin-2
2
Immunoglobulin G
2
Disulfides
2
Cyclophosphamide
2
CTLA-4 Antigen
2
Anterior Temporal Lobectomy
2
1,2-diaminocyclohexaneplatinum II citrate
2
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
Midazolam
×
1 year
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled